


RESEARCH ARTICLE

Effect of dexamethasone exposure on the neonatal unit on the school age lung function of children born very prematurely

Christopher Harris^{1,2} , Siobhan Crichton³ , Sanja Zivanovic^{1,2}, Alan Lunt^{1,2}, Sandy Calvert⁴, Neil Marlow⁵, Janet L. Peacock^{3,6} , Anne Greenough^{1,2,6} *

1 MRC & Asthma UK Centre for Allergic Mechanisms in Asthma, King's College London, London, United Kingdom, **2** Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom, **3** School of Population Health and Environmental Sciences, King's College London, London, United Kingdom, **4** Department of Child Health, St George's Hospital, London, United Kingdom, **5** Neonatal Medicine, University College, London, United Kingdom, **6** NIHR Biomedical Centre at Guy's and St Thomas NHS Foundation Trust and King's College London, London, United Kingdom

 These authors contributed equally to this work.
 ‡ JLP and AG are equal senior authors on this work.
 * anne.greenough@kcl.ac.uk



 OPEN ACCESS

Citation: Harris C, Crichton S, Zivanovic S, Lunt A, Calvert S, Marlow N, et al. (2018) Effect of dexamethasone exposure on the neonatal unit on the school age lung function of children born very prematurely. PLoS ONE 13(7): e0200243. <https://doi.org/10.1371/journal.pone.0200243>

Editor: Umberto Simeoni, Centre Hospitalier Universitaire Vaudois, FRANCE

Received: January 5, 2018

Accepted: June 24, 2018

Published: July 9, 2018

Copyright: © 2018 Harris et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This is a secondary analysis of a study originally funded by National Institute for Health Research (NIHR) Health Technology Assessment Programme. The current research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of

Abstract

The objective of this study was to determine the impact of postnatal dexamethasone treatment on the neonatal unit on the school age lung function of very prematurely born children. Children born prior to 29 weeks of gestational age had been entered into a randomised trial of two methods of neonatal ventilation (United Kingdom Oscillation Study). They had comprehensive lung function measurements at 11 to 14 years of age. One hundred and seventy-nine children born at a mean gestational age of 26.9 (range 23–28) weeks were assessed at 11 to 14 years; 50 had received postnatal dexamethasone. Forced expiratory flow at 75% (FEF₇₅), 50%, 25% and 25–75% of the expired vital capacity, forced expiratory volume in one second, peak expiratory flow and forced vital capacity and lung volumes including total lung capacity and residual volume were assessed. Lung function outcomes were compared between children who had and had not been exposed to dexamethasone after adjustment for neonatal factors using linear mixed effects regression. After adjustment for confounders all the mean spirometry results were between 0.38 and 0.87 standard deviations lower in those exposed to dexamethasone compared to the unexposed. For example, the mean FEF₇₅ z-score was 0.53 lower (95% CI 0.21 to 0.85). The mean lung function was lower as the number of courses of dexamethasone increased. In conclusion, postnatal dexamethasone exposure was associated with lower mean lung function at school age in children born extremely prematurely. Our results suggest the larger the cumulative dose the greater the adverse effect on lung function at follow-up.

the authors and not necessarily those of the NHS, the NIHR or the Department of Health. JLP is an NIHR Senior Investigator.

Competing interests: Professor Greenough has held grants from various manufacturers (Abbot Laboratories, MedImmune) and ventilator manufacturers (SLE). Professor Greenough has received honoraria for giving lectures and advising various manufacturers (Abbot Laboratories, MedImmune) and ventilator manufacturers (SLE). Professor Greenough is currently receiving a non-conditional educational grant from SLE. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials as detailed online in the guide for authors.

Introduction

Corticosteroids administered to prematurely born infants can facilitate early extubation and reduce the rate of bronchopulmonary dysplasia (BPD) [1, 2]. Postnatally administered corticosteroids have, however, been shown to adversely affect lung growth in rats resulting in emphysematous lungs with fewer airspaces and delayed alveolarization [3]. There are limited and conflicting data regarding the long term pulmonary effects of postnatal corticosteroids on prematurely born children. In a study of 16 children born between 24 to 29 weeks of gestation, who had been entered into a randomised controlled trial (RCT) at 10 days of age, no significant differences were found in respiratory morbidity between 7.8 and 9.2 years [4]. In a follow up of another RCT, no statistically significant differences were found in lung function results (forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), FEV₁/FVC ratio, peak expiratory flow (PEF), forced expiratory flow between 25% and 75% of VC (FEF_{25-75%})) at 13 to 17 years between the 68 prematurely born children who had received corticosteroids and the 74 who had received placebo at a median age of four weeks [5]. There were also no significant differences in inhaler use (relative risk (RR) 0.67, 95% CI 0.37 to 1.22), wheezing (RR 0.80, 95% CI 0.53 to 1.20) or cough (RR 1.19, 95% CI 0.67 to 2.23) between the two groups [5]. One study reported a positive effect in that only 48% of children who had received a 42 day tapering course of postnatal corticosteroids had an FEV₁ below the normal range at 8 to 11 years of age in comparison to 68% of the controls ($p = 0.03$) [6]. The parent reported incidence of asthma, however, was similar in the two groups [6] and a further study of those children reported no significant differences in impaired aerobic fitness between the two groups [7]. In contrast, in a cross-sectional study, 105 prematurely born children who had been exposed to postnatal corticosteroids, had lower FEV₁ ($p = 0.01$), FEF_{25-75%} ($p = 0.003$), and PEF ($p = 0.02$) at age 9–11 years [8]. It is important to note that none of those study populations [5–8] had been exposed to postnatal surfactant and few to antenatal corticosteroids.

The United Kingdom Oscillation Study (UKOS) was a randomised trial of two modes of neonatal ventilation involving 797 infants born prior to 29 weeks of gestational age. More than 90% of the infants were exposed both to antenatal corticosteroids and postnatal surfactant [9]. We previously demonstrated that administration of postnatal dexamethasone was associated with significantly increased proportions of children with respiratory hospital readmission: (0.35 vs 0.15, difference = 0.20; 95% CI: 0.08 to 0.31) and neurodevelopmental impairment (0.59 vs 0.45, difference = 0.14; 95% CI: 0.02 to 0.26) after adjustment for confounding [10]. The aim of this present study was to analyse the lung function results of those entered into the UKOS trial at 11 to 14 years [11] to test the hypothesis that those exposed to postnatal dexamethasone had lower mean lung function results.

Methods

Children from UKOS were invited to attend for follow-up at 11 to 14 years of age at King's College Hospital NHS Foundation Trust. Ethical approval was granted by the South Thames Multicentre Research Ethics Committee and by the South West London National Research Ethics Service Committee for the follow up study [11]. Parents gave informed, written consent.

Lung function testing was carried out as previously described [11]. FEF₇₅, FEF₅₀, FEF₂₅ and FEF₂₅₋₇₅, FEV₁, PEF and FVC were assessed by spirometry. Lung volumes were assessed using a helium-dilution technique (functional residual capacity, FRC_{He}) and plethysmography ((FRC_{pleth}), total lung capacity (TLC) and residual volume (RV)). Respiratory resistance was measured by impulse oscillometry at 5Hz and 20Hz. The diffusing capacity of the lungs for carbon monoxide was measured using a single breath technique. All tests were done in

accordance to guidance from the American Thoracic Society and the European Respiratory Society. The results were converted into z-scores to adjust for age, sex, and height [11], except for PEF and respiratory resistance which were expressed as the percentage predicted for height and sex [12, 13].

Data for postnatal corticosteroid exposure was captured when the original UKOS study was undertaken in 1998–2001. Correspondence confirmed that dexamethasone was the corticosteroid used in the postnatal period in all units. An average course of dexamethasone would be 0.25 mg twice daily for three days, followed by 0.15 mg twice daily for three days, followed by 0.05 mg twice daily for three days.

Statistical analysis

To examine the associations between postnatal dexamethasone use and lung function at follow-up, linear mixed effects regression models were used to allow for clustering of data arising from multiple births [14]. All other predictor variables were forced into the model and treated as fixed effects. Measures of dexamethasone use considered were: a yes/no indicator, the number of courses of dexamethasone (none, one, two or three) and the length of exposure to dexamethasone (0, 1–6, 7–12 or >12 days) [10]. Initially associations were explored in univariable models and then in a multivariable model. To adjust for potential confounders, the following factors were included in the multivariable models: sex, birth weight z-score, gestational age, maternal smoking during pregnancy, oxygen dependency at 36 weeks postmenstrual age (PMA), major cranial ultrasound abnormality, air leak, patent ductus arteriosus (PDA), pulmonary haemorrhage, mode of ventilation and age at the time of follow-up assessment. Sensitivity analyses were conducted to also adjust for antenatal steroids and postnatal surfactant. Differences in mean lung function results by dexamethasone exposure were also shown as the difference in the proportions with abnormal lung function using the fifth centile in healthy children to define abnormal. The distributional approach was used for these calculations to retain the same power as the comparison of means [15, 16] and followed the approach we used in previous work [11]. (Table D in [S1 File](#)).

A further set of sensitivity analyses were conducted to explore the robustness of the adjustment for confounders. This used propensity score matching to compare outcomes in children who had and had not been exposed to dexamethasone. Full details are given in [Table C in S1 File](#).

Subjects with complete data in the variables required for adjustment in the multivariable models or matching in the propensity score analysis were included in the analysis. Where one, but not all, lung function assessment results were available, cases were excluded only from analyses of the measures for which the data were missing. Analysis was conducted using Stata 13MP.

Results

Two hundred and forty-eight children attended for lung function assessment; 179 had complete data at baseline and were included in these analyses ([Fig 1](#)). There were no significant differences between those with and without complete data for the majority of the lung function results, except for RV and FRC_{pleth} z scores ([Table A in S1 File](#)). Similarly, there were no significant differences in baseline characteristics comparing those included ($n = 179$) and those with incomplete data ($n = 223$) ([Table B in S1 File](#)).

Fifty children (28%) had received at least one course of dexamethasone in the neonatal period and 129 were not exposed to dexamethasone ([Table 1](#)). The children exposed to dexamethasone had significantly lower mean birth weight and gestational age, were less likely to be




Fig 1. Study flow chart.

<https://doi.org/10.1371/journal.pone.0200243.g001>

multiples, a greater proportion had an air leak and have lower Apgar five minute scores and a greater proportion were oxygen dependent at 36 weeks PMA (Table 1).

Comparison of the lung function results of those exposed and not exposed to dexamethasone demonstrated significant differences in favour of those unexposed in all the results using linear mixed model adjustment, with differences in the means of the spirometry results ranging from 0.38 to 0.87 standard deviations (Table 2). The differences in mean z-scores for the spirometry, measures are expressed as the equivalent percentage of children with abnormal function. For example, the percentage of children with an abnormal FEF₇₅ is estimated as 21% in the non-exposed and 43% in the exposed group. The other spirometry measures show differences between the exposed and unexposed children ranging from 7.6 to 34 percentage points (Table 3).

Table 1. Characteristics of children who were or were not exposed to dexamethasone. The data are presented as the mean (SD) or n (%) unless otherwise shown.

	No dexamethasone exposure	Dexamethasone exposure	p-value
N	129	50	
Birth weight (grams)	939 (205)	810 (175)	<0.001
Birthweight SDS	-0.63 (0.98)	-0.90 (1.12)	0.11
Gestational age (weeks)	26.7 (1.2)	25.6 (1.3)	<0.001
Male sex	60 (47%)	31 (62%)	0.063
Multiple birth	37 (29%)	7 (14%)	0.041
Oxygen dependency at 36 weeks PMA	62 (48%)	43 (86%)	<0.001
Major ultrasound abnormality in neonatal period	16 (12%)	7 (14%)	0.775
Airleak	9 (7%)	12 (24%)	0.001
Patent ductus arteriosus	34 (26%)	20 (40%)	0.074
Pulmonary haemorrhage	5 (3.9%)	5 (10%)	0.109
HFOV	60 (47%)	29 (58%)	0.168
Apgar score at 5 mins (mean, range)	9 (8–9)	8 (7–9)	<0.001
Maternal smoking in pregnancy	32 (25%)	9 (18%)	0.331
Antenatal steroids	14 (88%)	47 (96%)	0.160
Postnatal surfactant	127 (98%)	49 (98%)	>0.999

<https://doi.org/10.1371/journal.pone.0200243.t001>

Table 2. Lung function and postnatal dexamethasone exposure.

Lung Function	N	No dexamethasone exposure	Dexamethasone exposure	Unadjusted		Adjusted using multiple regression	
		Mean (SD)	Mean (SD)	Difference (95% CI)	p-value	Difference (95% CI)	p-value
FEF ₇₅ z score	179	-0.95 (0.91)	-1.45 (0.71)	-0.46 (0.74 to -0.18)	0.001	-0.53* (-0.85 to -0.21)	0.002
FEF ₅₀ z score	179	-1.04 (0.89)	-1.71 (0.81)	-0.66 (0.94 to -0.38)	<0.001	-0.74 (-1.05 to -0.43)	<0.001
FEF ₂₅ z score	179	-0.82 (0.91)	-1.53 (0.86)	-0.70 (-0.99 to -0.41)	<0.001	-0.75 (-1.07 to -0.44)	<0.001
FEF ₂₅₋₇₅ z score	169	-1.24 (1.07)	-1.98 (1.05)	-0.70 (-1.06 to -0.35)	<0.001	-0.70 (-1.08 to -0.33)	<0.001
FEV ₁ z score	179	-0.55 (1.03)	-1.44 (1.03)	-0.86 (-1.20 to -0.53)	<0.001	-0.87 (-1.24 to -0.51)	<0.001
FVC z score	179	-0.24 (0.96)	-0.73 (1.11)	-0.46 (-0.79 to -0.13)	0.006	-0.38 (-0.75 to -0.01)	0.043
FEV ₁ :FVC z score	179	-1.17 (1.69)	-2.32 (2.11)	-1.14 (-1.74 to -0.55)	<0.001	-1.43 (-2.09 to -0.78)	<0.001
PEF % pred*	178	86.07 (14.64)	77.36 (13.98)	-8.34 (-13.06 to -3.62)	0.001	-10.74 (-16.06 to -5.41)	<0.001
RV z score	152	0.26 (1.09)	1.29 (1.67)	0.99 (0.53 to 1.45)	<0.001	0.86 (0.36 to 1.36)	0.001
FRC _{pleth} z	157	-0.11 (1.25)	0.39 (1.39)	0.49 (0.04 to 0.94)	0.031	0.39 (-0.11 to 0.90)	0.128
FRC _{hc} z score	168	-0.73 (1.09)	-0.42 (1.00)	0.32 (-0.04 to 0.68)	0.083	0.27 (-0.13 to 0.66)	0.186
DL _{CO} z score	149	-0.93 (1.11)	-1.04 (1.02)	-0.06 (-0.46 to 0.34)	0.764	0.09 (-0.33 to 0.52)	0.658
At 5 Hz	170	96.06 (21.38)	100.11 (27.03)	4.60 (-3.22 to 12.42)	0.249	9.57 (1.13 to 18.02)	0.026
At 20 Hz	170	93.94 (19.82)	91.28 (4.46)	-2.28 (-10.13 to 5.58)	0.570	2.49 (-6.27 to 11.25)	0.578

*expressed as percentage predicted for height and sex

<https://doi.org/10.1371/journal.pone.0200243.t002>

Table 3. Adjusted differences in mean lung function with equivalent differences in the proportions (as percentage) with abnormal lung function (below/above 5th centile for healthy population*).

Lung Function measure	N	Adjusted mean lung function (Table 2 in paper)	Percentage with abnormal lung function (rounded to 2 significant figures)		Adjusted difference in percentage with abnormal lung function
		Difference (exposed-unexpo) (95% CI)	No dexamethasone exposure	Dexamethasone exposure	Difference (exposed-unexpo) (95% CI)
FEF ₇₅ z score +	179	-0.53 (-0.85 to -0.21)	21%	43%	22% (12 to 33%)
FEF ₅₀ z score	179	-0.74 (-1.05 to -0.43)	22%	57%	34% (24 to 44%)
FEF ₂₅ z score	179	-0.75 (-1.07 to -0.44)	15%	47%	31% (21 to 41%)
FEF ₂₅₋₇₅ z score	169	-0.70 (-1.08 to -0.33)	35%	64%	28% (18 to 39%)
FEV ₁ z score	179	-0.87 (-1.24 to -0.51)	13%	42%	29% (20 to 39%)
FVC z score	179	-0.38 (-0.75 to -0.01)	8%	15%	7.6% (1.7 to 14%)
FEV ₁ :FVC z	179	-1.43 (-2.09 to -0.78)	38%	70%	32% (22 to 42%)
PEF % pred	178	-10.74 (-16.06 to -5.41)	-	-	-
RV z score	152	0.86 (0.36 to 1.36)	13%	35%	22% (12 to 32%)
FRC _{pleth} z	157	0.39 (-0.11 to 0.90)	-	-	-
FRC _{he} z score	168	0.27 (-0.13 to 0.66)	-	-	-
DL _{CO} z score	149	0.09 (-0.33 to 0.52)	-	-	-
At 5 Hz	170	9.57 (1.13 to 18.02)	-	-	-
At 20 Hz	170	2.49 (-6.27 to 11.25)	-	-	-

* Calculated where abnormality can be defined as below or above 5th centile for a healthy population and using a distribution approach [15, 16]

+ The percentage of children with abnormal FEF₇₅ was estimated as 21% in the non-exposed and 43% in the exposed group, a difference of 23% (95% CI: 13 to 33%) [12–13]

<https://doi.org/10.1371/journal.pone.0200243.t003>

Sensitivity analyses adjusting for confounding using propensity score matching gave very similar results to the linear mixed models (Table D in S1 File). Further sensitivity analysis adjusting for antenatal steroids and postnatal surfactant made no appreciable difference (Table E in S1 File). Similarly, adjustment for tobacco smoke exposure at age 11–14 [17] did not affect the estimates or statistical significance (data not shown).

The mean lung function was lower in children who had received more courses of dexamethasone compared to one course and this remained significant after adjustment for most measures (Table 4). Similar trends were seen with the length of exposure with longer exposure being associated with poorer mean lung function which remained significant after adjustment (Table 5).

Discussion

Our results from a secondary analysis suggest that postnatal dexamethasone exposure was associated with lower mean lung function at school age in children born very prematurely

Table 4. Lung function and number of postnatal dexamethasone courses.

	Unadjusted					Adjusted				
	None	One course difference (95% CI) p-value	Two courses difference (95% CI) p-value	Three courses difference (95% CI) p-value	Overall p-value	None	One course difference (95% CI) p-value	Two courses difference (95% CI) p-value	Three courses difference (95% CI) p-value	Test for trend p-value
N	129	35	11	4		129	35	11	4	
FEF ₇₅ z score	ref	-0.37 (-0.68 to -0.06) 0.021	-0.59 (-1.11 to -0.08) 0.024	-0.92 (-1.76 to -0.08) 0.032	0.006	ref	-0.48 (-0.81 to -0.14) 0.006	-0.59 (-1.16 to -0.03) 0.040	-1.02 (-1.88 to -0.15) 0.021	0.001
FEF ₅₀ z score	ref	-0.52 (-0.84 to -0.21) 0.001	-1.01 (-1.53 to -0.49) <0.001	-0.95 (-1.80 to -0.10) 0.029	<0.001	ref	-0.65 (-0.98 to -0.33) <0.001	-0.99 (-1.53 to -0.44) <0.001	-1.15 (-1.99 to -0.31) 0.007	<0.001
FEF ₂₅ z score	ref	-0.61 (-0.94 to -0.28) <0.001	-0.85 (-1.39 to -0.30) 0.002	-1.13 (-2.01 to -0.24) 0.012	<0.001	ref	-0.71 (-1.05 to -0.38) <0.001	-0.78 (-1.34 to -0.22) 0.006	-1.22 (-2.08 to -0.37) 0.005	<0.001
FEF ₂₅₋₇₅ z score*	ref	-0.49 (-0.88 to -0.10) 0.014	-1.22 (-1.85 to -0.58) <0.001	1.19 (-2.23 to -0.15) 0.024	<0.001	ref	-0.60 (-1.00 to -0.20) 0.003	-0.96 (-1.62 to -0.31) 0.004	-1.29 (-2.31 to -0.28) 0.013	<0.001
FEV ₁ z score	ref	-0.64 (-1.02 to -0.27) 0.001	-1.32 (-1.93 to -0.70) <0.001	-1.60 (-2.60 to -0.60) 0.002	<0.001	ref	-0.74 (-1.13 to -0.36) <0.001	-1.16 (-1.80 to -0.52) <0.001	-1.65 (-2.63 to -0.67) 0.001	<0.001
FVC z score	ref	-0.26 (-0.63 to 0.10) 0.158	-0.82 (-1.43 to -0.22) 0.007	-1.19 (-2.18 to -0.21) 0.017	0.005	ref	-0.27 (-0.67 to 0.12) 0.174	-0.59 (-1.25 to 0.06) 0.077	-1.06 (-2.06 to -0.05) 0.039	0.009
FEV ₁ :FVC z score	ref	-1.00 (-1.67 to -0.33) 0.003	-1.48 (-2.57 to -0.38) 0.008	-1.56 (-3.35 to 0.23) 0.088	0.002	ref	-1.30 (-2.00 to -0.59) <0.001	-1.82 (-2.99 to -0.64) 0.002	-1.98 (-3.77 to -0.18) 0.031	<0.001
PEF % of predicted**	ref	-8.11 (-13.35 to -2.87) 0.002	-3.51 (-12.10 to 5.07) 0.423	-23.27 (-37.33 to -9.22) <0.001	<0.001	ref	-10.27 (-15.85 to -4.70) <0.001	-6.55 (-15.88 to 2.77) 0.168	-26.51 (-40.91 to -12.11) <0.001	<0.001
RV z score***	ref	0.74 (0.23 to 1.25) 0.004	1.66 (0.81 to 2.52) <0.001	1.73 (-0.03 to 3.48) 0.053	<0.001	ref	0.68 (0.15 to 1.22) 0.011	1.47 (0.58 to 2.35) 0.001	1.27 (-0.45 to 2.99) 0.147	<0.001
FRC _{pleth} z score****	ref	0.33 (-0.17 to 0.82) 0.194	1.10 (0.23 to 1.97) 0.013	0.45 (-1.34 to 2.24) 0.621	0.065	ref	0.25 (-0.29 to 0.78) 0.363	1.11 (0.18 to 2.04) 0.020	0.14 (-0.17 to 1.96) 0.877	0.063
FRC _{hc} z score	ref	0.36 (-0.04 to 0.77) 0.080	0.11 (-0.54 to 0.76) 0.751	0.50 (-0.56 to 1.56) 0.353	0.299	ref	0.29 (-0.13 to 0.71) 0.178	0.18 (-0.52 to 0.88) 0.616	0.22 (-0.84 to 1.28) 0.689	0.338
DL _{CO} z score	ref	0.07 (-0.37 to 0.51) 0.762	-0.13 (-0.90 to 0.64) 0.735	-1.11 (-2.33 to 0.12) 0.077	0.332	ref	0.19 (-0.26 to 0.64) 0.412	0.11 (-0.68 to 0.89) 0.785	-1.00 (-2.21 to 0.21) 0.106	0.680
Respiratory resistance (% predicted)										

(Continued)

Table 4. (Continued)

	Unadjusted					Adjusted				
	None	One course difference (95% CI) p-value	Two courses difference (95% CI) p-value	Three courses difference (95% CI) p-value	Overall p-value	None	One course difference (95% CI) p-value	Two courses difference (95% CI) p-value	Three courses difference (95% CI) p-value	Test for trend p-value
At 5 Hz	ref	4.03 (-4.65 to 12.72) 0.362	10.06 (-4.43 to 24.55) 0.174	-6.96 (-33.17 to 19.25) 0.603	0.436	ref	9.55 (0.60 to 18.50) 0.036	12.86 (-2.31 to 28.04) 0.097	-1.77 (-27.87 to 24.32) 0.894	0.093
At 20Hz	ref	0.82 (-7.91 to 9.56) 0.854	-5.54 (-20.16 to 9.07) 0.457	-25.71 (-51.84 to 0.41) 0.054	0.227	ref	4.63 (-4.63 to 13.89) 0.327	-0.59 (-16.24 to 15.06) 0.941	-20.74 (-47.49 to 6.02) 0.129	0.669

Footnote: differences are exposed–unexposed.

The children who received no dexamethasone are the reference group for all comparisons.

Some lung function results were only available for certain children

*169

**178

*** 152

**** 157

<https://doi.org/10.1371/journal.pone.0200243.t004>

after adjusting for neonatal factors using careful adjustment for confounding with linear mixed effects modelling. In particular, we have shown significant differences in airway function and increased gas trapping as indicated by a higher residual volume. These results were replicated using a different form of adjustment, propensity score matching. The difference observed is substantial being over one half of a standard deviation for FEF₇₅, equivalent to a difference of 22 percentage points in children with abnormal lung function. In addition, our results suggest that the longer the course or the greater the number of courses the greater the observed reduction in lung function. These results were consistent with our earlier study that showed an association between dexamethasone exposure and poor respiratory and neurological outcomes in infancy in the same population and using the same rigorous statistical approach to control for confounding [10]. In contrast, results of an earlier study had suggested that a longer duration of the corticosteroid might improve respiratory outcomes. Mean lung function at 15 years of age was significantly better in those who had received a 42 day course compared to those who had received an 18 day course [18]. There were, however no significant differences between those who received the 42 day course or the placebo and only 22 children in total were included in the study. Our analysis was of a larger cohort and we adjusted carefully for possible confounders.

Our results of impaired lung function following postnatal dexamethasone exposure are consistent with findings in animal models showing abnormal lung function. Although, we highlight that the significant reduction in airway function was more than the reduction in lung volume. In an early animal study [3], postnatal corticosteroids resulted in emphysematous lungs with fewer air spaces and delayed alveolarisation. A more recent study has highlighted that dexamethasone treatment of newborn rats resulted in delayed expression of elastin and smooth muscle actin and the parenchymal expression of tenascin-C (TNC) was delayed [19]. The authors postulated that neonatal corticosteroids impaired the first phase of alveolarisation by altering TNC and elastin expression [19]. In mice treated with dexamethasone, the mRNA expression level of fibrillin-1, which is a key protein reinforcing elastic fibres, were lower than in controls. Fibrillin-1 consists of microfibrils as a scaffold to form elastic fibres and fibulin-5.

Table 5. Lung function and length of exposure to postnatal dexamethasone (days).

	Unadjusted					Adjusted				
	0	1–6, Difference (95% CI) p-value	7–12, Difference (95% CI) p-value	>12, Difference (95% CI) p-value	Overall p-value	0	1–6 days, Difference (95% CI) p-value	7–12 days, Difference (95% CI) p-value	>12 days, Difference (95% CI) p-value	Test for trend p-value
N	129	6	21	22		129	6	21	22	
FEF ₇₅ z score	ref	-0.23 (-0.89 to 0.43) 0.490	-0.34 (-0.74 to 0.05) 0.086	-0.63 (-1.01 to -0.25) 0.001	0.008	ref	-0.36 (-1.01 to 0.30) 0.286	-0.45 (-0.86 to -0.03) 0.034	-0.68 (-1.10 to -0.26) 0.002	<0.001
FEF ₅₀ z score	ref	-0.51 (-1.16 to 0.14) 0.126	-0.46 (-0.85 to -0.06) 0.025	-0.89 (-1.28 to -0.50) <0.001	<0.001	ref	-0.61 (-1.22 to 0.01) 0.054	-0.60 (-1.00 to -0.19) 0.004	-0.95 (-0.14 to -0.54) <0.001	<0.001
FEF ₂₅ z score	ref	-0.80 (-1.49 to -0.10) 0.025	-0.55 (-0.96 to -0.14) 0.009	-0.83 (-1.23 to -0.43) <0.001	<0.001	ref	-0.80 (-1.45 to -0.15) 0.017	-0.67 (-1.08 to -0.26) 0.001	-0.84 (-1.26 to -0.42) <0.001	<0.001
FEF ₂₅₋₇₅ z score*	ref	-0.67 (-1.46 to 0.13) 0.099	-0.55 (-1.04 to -0.06) 0.028	-0.84 (-1.33 to -0.35) 0.001	0.002	ref	-0.73 (-1.43 to -0.02) 0.043	-0.64 (-1.13 to -0.14) 0.001	-0.76 (-1.27 to -0.25) 0.003	0.008
FEV ₁ z score	ref	-0.87 (-1.77 to -0.07) 0.033	-0.53 (-1.00 to -0.06) 0.027	-1.17 (-1.63 to -0.71) <0.001	<0.001	ref	-0.88 (-1.63 to -0.14) 0.020	-0.63 (-1.10 to -0.16) 0.009	-1.13 (1.61 to -0.65) <0.001	<0.001
FVC z score	ref	-0.80 (-1.58 to -0.02) 0.045	-0.08 (-0.54 to -0.38) 0.731	-0.73 (-1.18 to -0.28) 0.001	0.005	ref	-0.78 (-1.55 to -0.01) 0.047	-0.07 (-0.55 to 0.40) 0.765	-0.57 (-1.06 to -0.09) 0.020	0.049
FEV ₁ :FVC z score	ref	-0.45 (-1.84 to 0.94) 0.523	-0.98 (-1.81 to -0.15) 0.021	-1.51 (-2.32 to -0.69) <0.001	0.001	ref	-0.67 (-2.02 to 0.68) 0.329	-1.30 (-2.16 to -0.45) 0.003	-1.83 (-2.70 to -0.96) <0.001	<0.001
PEF % predicted**	ref	-8.99 (-19.85 to 1.87) 0.105	-9.55 (-16.21 to -2.59) 0.005	-7.61 (-14.10 to 1.13) 0.021	0.005	ref	-9.96 (-20.27 to 0.34) 0.058	-11.79 (-18.81 to -4.77) 0.001	-10.08 (-17.12 to -2.98) 0.005	<0.001
RV z score***	ref	1.58 (0.48 to 2.67) 0.005	0.21 (-0.41 to 0.82) 0.510	1.59 (0.97 to 2.22) <0.001	<0.001	ref	1.37 (0.31 to 2.44) 0.012	0.21 (-0.41 to 0.82) 0.516	1.41 (0.77 to 2.05) <0.001	<0.001
FRC _{pleth} z score****	ref	0.78 (-0.25 to 1.80) 0.138	0.04 (-0.58 to 0.66) 0.899	0.83 (0.1 to 1.47) 0.011	0.040	ref	0.61 (-0.43 to 1.65) 0.250	-0.01 (-0.65 to 0.64) 0.980	0.77 (0.08 to 1.45) 0.028	0.083
FRC _{he} z score	ref	0.36 (-0.47 to 1.19) 0.392	0.28 (-0.22 to 0.77) 0.273	0.35 (-0.15 to 0.86) 0.170	0.380	ref	0.26 (-0.56 to 1.07) 0.538	0.22 (-0.29 to 0.73) 0.403	0.33 (-0.20 to 0.86) 0.223	0.184
DL _{CO} z score	ref	0.34 (-0.69 to 1.37) 0.517	-0.07 (-0.61 to 0.47) 0.790	-0.07 (-0.64 to 0.50) 0.803	0.902	ref	0.35 (-0.65 to 1.34) 0.493	0.07 (-0.48 to 0.62) 0.795	0.07 (-5.06 to 0.65) 0.803	0.7162
Respiratory resistance % predicted										

(Continued)

Table 5. (Continued)

	Unadjusted					Adjusted				
	0	1–6, Difference (95% CI) p-value	7–12, Difference (95% CI) p-value	>12, Difference (95% CI) p-value	Overall p-value	0	1–6 days, Difference (95% CI) p-value	7–12 days, Difference (95% CI) p-value	>12 days, Difference (95% CI) p-value	Test for trend p-value
At 5 Hz	ref	17.35 (0.51 to 34.20) 0.043	-2.15 (-12.74 to 8.44) 0.690	8.85 (-2.33 to 20.03) 0.121	0.101	ref	20.41 (4.34 to 36.47) 0.013	3.30 (-7.56 to 14.16) 0.552	12.68 (0.90 to 24.47) 0.035	0.054
At 20 Hz	ref	11.41 (-6.57 to 29.39) 0.214	-4.36 (-15.06 to 6.35) 0.425	-4.35 (-15.73 to 7.03) 0.454	0.395	ref	12.24 (-5.30 to 29.79) 0.171	-0.05 (-11.33 to 11.23) 0.993	1.62 (-10.66 to 13.90) 0.796	0.828

Footnote: Diff: difference in means exposed—unexposed
 The children who received no dexamethasone are the reference group for all comparisons
 Some lung function results were only available for certain children

*169
 **178
 *** 152
 **** 157

<https://doi.org/10.1371/journal.pone.0200243.t005>

On the other hand, the peak mRNA expression of tropelastin, the main component in elastic fibres, occurred earlier in the dexamethasone group [20]. The authors postulated this imbalance in the expression of tropelastin and microfibril might interfere with the efficient formation of elastic fibres, resulting in thinning of the alveolar walls [20]. Indeed, in the dexamethasone group there were fewer and larger alveoli [20]. Furthermore, we did not find any significant difference in diffusing capacity results between the two groups.

Our study has strengths and limitations. We report a wide range of lung function measures at 11 to 14 years of age in large number of extremely prematurely born children. Ninety per cent of the children had been exposed to antenatal corticosteroids and nearly all received postnatal surfactant and hence our population is similar to those currently receiving intensive care. We included in our modelling oxygen dependency at 36 weeks PMA as this has been associated with poorer lung function at follow up. We do not report the results of a randomised trial, but analysed our data using rigorous statistical modelling to control for confounding due to differences in neonatal factors and clustering due to multiple births (25% in our sample). The analyses for dexamethasone exposure as a yes/no outcome were also undertaken using propensity score matching. It was not possible to use propensity score matching for the three measures of dexamethasone exposure, that is timing of administration, number of courses and days of exposure due to the small numbers in the different dexamethasone-use categories and so no sensitivity analyses were possible for those outcomes. We do not report whether the lung function abnormalities were associated with an increased need for medications, excess symptoms or exercise intolerance. We intend to investigate this when we assess the UKOS population when they are older.

There were no significant differences in the acute outcomes in the children who had been entered into our RCT of two neonatal ventilation modes [9], but at 11–14 years mean lung function results were superior in the HFOV group [11]. Adjustment for mode of ventilation was made in this present analysis and did not explain the difference in outcomes by dexamethasone exposure. We found no evidence of differences in those with complete or incomplete data and so we consider that our results are generalizable to extremely prematurely born children. These data are observational and so we cannot exclude the possibility that the

associations observed are due to unmeasured residual confounding, but we made every effort to control for confounders.

In conclusion, our results suggest postnatal dexamethasone exposure was associated with lower lung function at 11–14 years of age in children born extremely prematurely. In addition, our results suggest the larger the cumulative dose the worse the lung function at follow-up.

Supporting information

S1 File. Online supplement. Table A: Lung function at follow up of children with and without complete data.

Table B: Baseline characteristics of the infants included and not included due to missing lung function data.

Table C: Mean FEF₇₅ z-score by neonatal factors (n = 179).

Table D: Lung function and postnatal dexamethasone exposure: sensitivity analyses adjusted for confounding using propensity score matching.

Table E: Sensitivity analyses adjusting for antenatal steroids and postnatal surfactant.

Table F: Random effects estimates from adjusted models presented in [Table 2](#) main paper. (DOC)

Acknowledgments

Funding: This is a secondary analysis of a study originally funded by National Institute for Health Research (NIHR) Health Technology Assessment Programme. The current research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London (Professors Greenough and Peacock).

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. JLP is an NIHR Senior Investigator.

Author Contributions

Conceptualization: Siobhan Crichton, Sanja Zivanovic, Alan Lunt, Sandy Calvert, Neil Marlow, Janet L. Peacock, Anne Greenough.

Data curation: Christopher Harris, Siobhan Crichton, Sanja Zivanovic, Alan Lunt.

Formal analysis: Christopher Harris, Siobhan Crichton, Sanja Zivanovic, Alan Lunt, Sandy Calvert, Janet L. Peacock.

Investigation: Anne Greenough.

Methodology: Anne Greenough.

Project administration: Anne Greenough.

Supervision: Anne Greenough.

Validation: Anne Greenough.

Writing – original draft: Anne Greenough.

Writing – review & editing: Christopher Harris, Sanja Zivanovic, Alan Lunt, Sandy Calvert, Neil Marlow, Janet L. Peacock, Anne Greenough.

References

1. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev.* 2017; 10: CD001146. <https://doi.org/10.1002/14651858.CD001146.pub5> PMID: 29063585
2. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev.* 2017; 10: CD001145. <https://doi.org/10.1002/14651858.CD001145.pub4> PMID: 29063594
3. Tschanz SA, Damke BM, Burri PH. Influence of postnatally administered glucocorticoids on rat lung growth. *Biol Neonate.* 1995; 68: 229–245. <https://doi.org/10.1159/000244241> PMID: 8580214
4. Mieskonen S, Eronen M, Malmbeg LP, Turpenen M, Kari MA, Hallman M. Controlled trial of dexamethasone in neonatal chronic lung disease: an 8 year follow up of cardiopulmonary function and growth. *Acta Paediatr.* 2003; 92: 896–904. PMID: 12948063
5. Jones RA, Collaborative Dexamethasone Trial Follow-up Group. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: II. Respiratory status, growth, and blood pressure. *Pediatrics.* 2005; 116: 379–384. <https://doi.org/10.1542/peds.2004-1819> PMID: 16061592
6. Nixon PA, Washburn LK, Schechter MS, O'Shea TM. Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. *J Pediatr.* 2007; 150: 345–350. <https://doi.org/10.1016/j.jpeds.2006.12.013> PMID: 17382108
7. Nixon PA, Washburn LK, Mudd LM, Webb HH, O'Shea TM. Aerobic fitness and physical activity levels of children born prematurely following randomization to postnatal dexamethasone. *J Pediatr.* 2011; 158: 65–70. <https://doi.org/10.1016/j.jpeds.2010.07.007> PMID: 20732688
8. Smith LJ, van Asperen PP, McKay KO, Selvadurai H, Fitzgerald DA. Post-natal corticosteroids are associated with reduced expiratory flows in children born very preterm. *J Paediatr Child Health.* 2011; 47: 448–454. <https://doi.org/10.1111/j.1440-1754.2010.01992.x> PMID: 21707820
9. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, et al; United Kingdom Oscillation Study Group. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. *N Engl J Med.* 2002; 347: 633–642. <https://doi.org/10.1056/NEJMoa020432> PMID: 12200550
10. Qin G, Lo JW, Marlow N, Calvert SA, Greenough A, Peacock JL. Postnatal steroids and neurodevelopmental and respiratory outcomes at two years in babies born extremely preterm. *PLoS ONE.* 2017; 12: e0181176. <https://doi.org/10.1371/journal.pone.0181176> PMID: 28723921
11. Zivanovic S, Peacock J, Alcazar-Paris M, Lo JW, Marlow N, Calvert S; United Kingdom Oscillation Study Group. Late outcomes of a randomized trial of high-frequency oscillation in neonates. *N Engl J Med.* 2014; 370: 1121–1130. <https://doi.org/10.1056/NEJMoa1309220> PMID: 24645944
12. Rosenthal M, Bain SH, Cramer D, Helms P, Denison D, Bush A, et al. Lung function in which children aged 4 to 19 years: 1–Spirometry. *Thorax.* 1993; 48: 794–802. PMID: 8211868
13. Nowowiejska B, Tomalak W, Radlinski J, Siergiejko G, Latawiec W, Kaczmarski M. Transient reference values for impulse oscillometry for children aged 3–18 years. *Pediatr Pulmonol.* 2008; 43: 1193–1197. <https://doi.org/10.1002/ppul.20926> PMID: 18988256
14. Sauzet O, Wright K, Marston L, Brocklehurst P, Peacock JL. Modelling the hierarchical structure in data sets with very small clusters: a simulation study to explore the effect of the proportion of clusters when the outcome is continuous. *Stat Med.* 2013; 32: 1429–1439. <https://doi.org/10.1002/sim.5638> PMID: 23027676
15. Peacock JL, Sauzet O, Ewings SM, Kerry SM. Dichotomizing continuous data while retaining statistical power using a distributional approach. *Stat Med.* 2012; 31: 3089–3103. <https://doi.org/10.1002/sim.5354> PMID: 22865598
16. Sauzet O, Breckenkamp J, Borde T, Brenne S, David M, Razum O, et al. A distributional approach to obtaining adjusted comparisons of proportions of a population at risk. *Emerg Themes Epidemiol.* 2016; 13: 8. <https://doi.org/10.1186/s12982-016-0050-2> PMID: 27279891
17. Lo J, Zivanovic S, Lunt A, Alcazar-Paris M, Andradi G, Thomas M, Marlow N, Calvert S, Peacock J, Greenough A. Longitudinal assessment of lung function in extremely prematurely born children. *Pediatr Pulmonol.* 2018; 53: 324–331. <https://doi.org/10.1002/ppul.23933> PMID: 29316378
18. Gross SJ, Anbar RD, Mettelman BB. Follow up at 15 year of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. *Pediatrics.* 2005; 115: 681–687. <https://doi.org/10.1542/peds.2004-0956> PMID: 15741372

19. Roth-Kleiner M, Berger TM, Gremlich S, Tschanz SA, Mund SI, Post M, et al. Neonatal steroids induce a down-regulation of tenascin-C and elastin and cause a deceleration of the first phase and an acceleration of the second phase of lung alveolarization. *Histochem Cell Biol.* 2014; 14: 75–84.
20. Kamei M, Miyajima A, Fujisawa M, Matsuoka Y, Hirota T. Effects of postnatal dexamethasone treatment on mRNA expression profiles of genes related to alveolar development in an emphysema model in mice. *J Toxicol Sci.* 2014; 39: 665–670. PMID: [25056791](https://pubmed.ncbi.nlm.nih.gov/25056791/)